What is Zumenon®?

Zumenon® is indicated for estrogen deficiency symptoms in postmenopausal women at least 6 months since last menses.

Prescribing Information

Why 17β estradiol?

  • Non-equine
  • Body-identical 17β estradiol

Indications of Zumenon®

Zumenon® is an estrogen only continuous HRT for women with or without a uterus. In general, treatment should start with Zumenon® 1mg. Depending on the clinical response, the dosage can afterwards be adjusted to individual need. If the woman still has estrogen deficiency symptoms the dosage can be increased by using Zumenon® 2mg.1

Regime Dose Bone protection Pack Price (£)2
Zumenon® Continuous
Estrogen only
1mg 3x28 6.89
Zumenon® Continuous
Estrogen only
2mg 3x28 6.89

These products are additionally licensed for the prevention of osteoporosis in post-menopausal women at high risk of the future fractures who are intolerant of, or contraindicated for, other medical products.

Add a progestogen if used in women with a uterus. This could be a separately prescribed therapy such as a 52mg intrauterine delivery system with a license for endometrial protection or micronised progesterone. You may also consider a combined HRT preparation such as Femoston® or Femoston®-conti (estradiol + dydrogesterone).

Benefits of oral estradiol therapy

The active ingredient, 17β-estradiol is a regulated bioidentical hormone (or body identical hormone) and is similar to its biological equivalent.3 It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms.

  • Relief of estrogen-deficiency symptoms1
  • Relief of menopausal symptoms was achieved during the first few weeks of treatment1
  • Hot flushes have been shown to be significantly reduced with 1 mg and 2 mg 17β-estradiol at 4 weeks1
  • Reference

    1. 1) Zumenon® 1mg and 2mg Summary of Product Characteristics.
    2. 2) MIMS September 2021. www.mims.co.uk.
    3. 3) Hamoda H et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health. October 2020.


Femoston is a combination of 17β estradiol and dydrogesterone, which is indicated for postmenopausal women at least 6 months since last menses to provide relief from vasomotor symptoms.


With multiple products including estrogen only, sequential and continuous combined, view our MyWay HRT range to discover our products and availability.


Date of preparation: November 2021

HCP Disclaimer

This website is intended for UK healthcare professionals only.

hcp popup title

Viatris Connect is an online platform for UK healthcare professionals.

Across the website you will find news, blogs and product information.

FREE Menopause and HRT webinars available to watch by registering to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.